secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tectonic Therapeutic, Inc. (TECX)
CIK:        0001681087
Form:       8-K
Filed at:   2026-02-26T23:59:59+00:00
Accession:  0001193125-26-076843
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tectonic Q4 net loss $19.2M; TX45 Phase 1b positive, TX2100 Phase 1a started
----------------------------------------------------------------------------

- Q4 net loss $19.2M (vs $12.4M YoY); R&D expenses $16.3M on advancing pipeline.
- Cash and equivalents $253.8M as of Dec 31, 2025; expected cash runway into Q4 2028.
- TX45 Phase 1b in PH-HFrEF showed 29.2% reduction in PCWP and 17.3% cardiac output improvement.
- TX2100 Phase 1a in HHT randomized first subject Feb 2026; topline results expected Q4 2026.
- François Nader appointed independent director effective April 1, 2026, to also serve as Board Chair.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1681087/000119312526076843/0001193125-26-076843-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1681087/000119312526076843/tecx-20260226.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-076843

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer